NSCLC (NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes aim at Hard-to-Treat lung cancer mutation
Disease control Not yet recruitingThis study tests a new drug, JMKX001899, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to prior treatments. About 472 adults will receive either the targeted pill or c…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Jemincare • Aim: Disease control
Last updated May 16, 2026 23:49 UTC
-
New drug duo aims to shrink lung tumors before surgery in targeted therapy trial
Disease control Not yet recruitingThis study tests whether giving a high dose of firmonertinib (a targeted pill) plus bevacizumab (an IV drug that blocks blood vessel growth) before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). About 62 adults whose cancer …
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
New combo therapy aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether a new combination of targeted radiation, immunotherapy, and chemotherapy can improve outcomes for people with early-stage non-small-cell lung cancer before they have surgery. The treatment is given before surgery to shrink the tumor and increase the chanc…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug duo aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether giving two drugs (sacituzumab tirumotecan and toripalimab) before surgery can help shrink tumors in people with stage II to IIIB non-small cell lung cancer. About 38 adults whose cancer does not have certain genetic changes will receive the combination, t…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for lung cancer patients: drug duo targets tumors after standard therapy fails
Disease control Not yet recruitingThis study tests a combination of two drugs (sacituzumab tirumotecan and furmonertinib) in 45 adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to initial treatment. The goal is to see if the combo can sh…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New trial aims to stop cancer from accelerating on immunotherapy alone
Disease control Not yet recruitingThis study is for people with advanced non-small cell lung cancer that has a high level of a protein called PD-L1. Some patients with a specific blood marker are at risk of their tumors growing faster when treated with immunotherapy alone. The trial will compare standard immunoth…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Università Vita-Salute San Raffaele • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Lung cancer study aims to decode immune secrets from tiny biopsies
Knowledge-focused Not yet recruitingThis study looks at how the immune system and certain genes affect treatment in people with advanced non-small cell lung cancer. Researchers will collect small tumor samples before and during treatment to study immune markers. The goal is to learn more about why some patients res…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated May 16, 2026 23:53 UTC